Assessment of Long-term Changes in Lower Urinary Tract Symptoms in Patients With Prostate Cancer Who Underwent Low-dose-rate Prostate Brachytherapy

Patient age as a predictive factor in biochemical recurrence following brachytherapy: Oncological outcomes at a single center

“…Iodine-125 low-dose-rate brachytherapy (LDR-BT) is a treatment modality used in both localized and advanced prostate cancer (PCa). 1 , 2 Over the past two decades, the radiation dose delivered by either external beam radiation therapy (EBRT) or brachytherapy has increased, resulting in decreased biochemical recurrence (BCR). 3 According to the D'Amico risk stratification 4 and the Phoenix definition, 5 the 5-year biochemical recurrence-free survival (BRFS) in patients with PCa who underwent LDR-BT with or without androgen deprivation therapy (ADT) and/or EBRT was 92.1–98.6% in low-risk PCa, 86.0–97.3% in intermediate-risk PCa, and 78–95.2% in high-risk PCa.…”

Chronological changes of lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer using SpaceOAR® system

“…reported long-term changes of LUTS in PCa patients who underwent LDR-BT. 25 The IPSS, OABSS, and IPSS-QOL were worsened immediately after LDR-BT compared to preoperative scores, and symptoms improved with time and returned to baseline after 18–36 months. 25 Onishi et al.…”

“… 25 The IPSS, OABSS, and IPSS-QOL were worsened immediately after LDR-BT compared to preoperative scores, and symptoms improved with time and returned to baseline after 18–36 months. 25 Onishi et al. investigated chronological changes of LUTS in patients who received LDR-BT for PCa treatment using the IPSS, OABSS, IPSS-QOL, UFM, and PVR.…”

“… 24 Several studies revealed the chronological changes of LUTS after LDR-BT. 25 , 26 Iinuma et al. reported long-term changes of LUTS in PCa patients who underwent LDR-BT.…”

Direct Comparison of Two Different Definitions with Biochemical Recurrence after Low-Dose-Rate Brachytherapy for Prostate Cancer

“…Low-dose-rate brachytherapy (LDR-BT) employs the use of a permanent radioactive seed embedded in the prostate and is one of the treatment options for patients diagnosed with low or good intermediate risk disease (low volume and Gleason grade [GG]2) [ 2 , 3 ], prostate volume (PV) less than 50 cm 3 , and the International Prostate Symptom Score of 12 or less [ 4 ]. Recently, trimodality therapy combining ADT, external-beam RT (EBRT), and LDR-BT has become one of the standard treatments for high-risk and locally advanced PCa, and relatively better oncologic outcomes, including biochemical recurrence-free survival (BRFS), metastatic-free survival, and overall survival, have been achieved in these patients [ 5 , 6 , 7 ].…”